Home > Result Summaries: Compounds > ropinirole > Result Summary for 101468/054

Result Summary for 101468/054

Result Summary

Protocol ID:	101468/054
Clinical Study ID:	SKF 101468-054
Official Title:	A Double-blind, Placebo Controlled, Parallel Group Study of Oral Doses of Ropinirole for Six Months in the Treatment of Early Parkinsonian Patients Not Receiving Dopaminergic Therapy
Phase:	Phase 3
Study Indications or Diseases:	Parkinson Disease
Generic Name:	ropinirole
Trade/Product Name:	requip;requip
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Population pharmacokinetics of ropinirole in patients with Parkinson’s disease. Beerahee A, Nichols AI, Aluri J et al. British Pharmacological Society, Brighton, UK, Dec 18–20 1996. Br J Clin Pharmacol 1997; 43: 556–557P Ropinirole, a non-ergoline D2 agonist, is effective in early parkinsonian patients not treated with l-dopa. Wheadon DE, Wilson-Lynch K, Gardiner D, Kreider MS. International Congress of Movement Disorders, Vienna, Austria, Jun 17–21 1996. Mov Disord 1996; 11(suppl 1): 162: P601 Response of tremor in untreated Parkinson’s disease to therapy with ropinirole. Schrag A, Keens J, Warner J, on behalf of the Ropinirole Study Group. European Federation of Neurological Societies, Lisbon, Portugal, Sep 7–11 1999. Eur J Neurol 1999; 6(suppl 3): 19–20 Resting tremor and postural/action tremor in early Parkinson’s disease (PD): efficacy of ropinirole compared with bromocriptine, l-dopa and placebo. Schrag A, Keens J, Warner J on behalf of the Ropinirole Study Group. Tremor: Basic Mechanisms and Clinical Aspects, Kiel, Germany, Jul 11–12 1997. Abstracts and Consensus Statement, p49 (abstracts) The effect of selegiline on the efficacy and safety of ropinirole in early and adjunct therapy studies in Parkinson’s disease. Fuell DL, Kreider M, Gardiner D. International Symposium on Parkinson’s Disease, London, UK, Mar 23–26 1997. Mov Disord 1997; 12(suppl 1): 116: P437 Ropinirole for the treatment of tremor in early Parkinson’s disease. Schrag A, Keens J, Warner J. Eur J Neurol 2002; 9: 253–257 Population pharmacokinetics of ropinirole in parkinsonian patients. Beerahee A, Nichols AI, Aluri J, Citerone D, Darwish M. American Society of Health-System Pharmacists, San Francisco, USA, 8–12 Dec 1996. Int Pharmaceutical Abstracts 1996; 33: 21(15 Nov) Dosing with ropinirole in a clinical setting. Korczyn AD, Rascol O, Adler CH, Warner J. International Congress on Parkinson’s Disease, Vancouver, Canada, Jul 24–28 1999. Parkinsonism Rel Disord 1999; 5(suppl): S77: P-TU-105 Optimal dosing with ropinirole in a clinical setting. Korczyn AD, Rascol O, Adler CH, Warner J. European Federation of Neurological Societies, Lisbon, Portugal, Sep 7–11 1999. Eur J Neurol 1999; 6(suppl 3): 132: P413 Ropinirole for the treatment of early Parkinson’s disease. Adler CH, Sethi KD, Hauser RA et al., for the Ropinirole Study Group. Neurology 1997; 49: 393–399 Dosing with ropinirole in a clinical setting. Korczyn AD, Thalamas C, Adler CH. Acta Neurol Scand 2002; 106: 200–204 The efficacy and safety of ropinirole, a novel non-ergoline selective D2 agonist, for the treatment of early Parkinson’s disease. Brooks DJ, Fuell D, Kreider MS. International Symposium on Parkinson’s Disease, London, UK, Mar 23–26 1997. Mov Disord 1997; 12(suppl 1): 62: P234 Efficacy and safety of ropinirole as early therapy for Parkinson’s disease. Kreider MS, Wilson-Lynch K, Gardiner D, Wheadon DE. Gerontological Society of America, Washington, USA, Nov 17–21 1996. Gerontologist 1996; 36(special issue 1): 271 The efficacy and safety of ropinirole in early parkinsonian patients not receiving dopaminergic therapy: a multicenter double-blind study. Wheadon D, Wilson-Lynch K, Gardiner D, Kreider M. American Academy for Neurology, San Francisco, USA, Mar 23–30 1996. Neurology 1996; 46(suppl 2): A159